Business Context and Reporting Period
This Form 8-K was filed by Gladstone Capital Corporation on October 22, 2007. The report discloses a specific investment event rather than periodic financial results.
Key Financial Metrics
The filing details a specific capital deployment but does not provide consolidated revenue, profit, cash flow, or margin data for the company.
- Investment Amount: Approximately $27.3 million.
- Investment Type: Purchase of senior debt.
- Target Company: Reliable Biopharmaceutical Corporation and its subsidiaries.
- Financing Source: Proceeds from borrowings under a revolving credit facility with Deutsche Bank A.G.
Material Changes and Investment Details
The primary material event is the acquisition of a senior debt position in Reliable Biopharmaceutical Corporation, a St. Louis-based developer of advanced ingredients and chemicals for pharmaceutical and biological products. The transaction structure includes a line of credit facility with a borrowing capacity of up to $5.0 million.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the inherent nature of the debt investment. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the terms and interest rate of the senior debt purchased in Reliable Biopharmaceutical Corporation.
- Confirm the impact of the $27.3 million outflow on the company's remaining liquidity and available borrowing capacity under the Deutsche Bank facility.
- Review the financial health and creditworthiness of Reliable Biopharmaceutical Corporation as the underlying borrower.
- Check subsequent filings for any covenant breaches or additional drawdowns on the $5.0 million line of credit.